DRKS00010275招募中1 期
A Phase 1/2, Randomized, Double-blind,Placebo-controlled, Multiple-ascending-dose Studyto Evaluate the Efficacy, Safety, and Pharmacokineticsof MEDI0382 in Overweight and Obese Subjectswith a History of Type 2 Diabetes Mellitus - MEDI0382 MAD
MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC0 个研究点目标入组 107 人开始时间: 2016年4月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 107
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •The study population will consist of male or female adults, 18 through 65 years of age with T2DM and body mass index 27 to 40 kg/m2 (inclusive), without significant late diabetic complications. Subjects should have been treated with a stable dose of oral blood glucose lowering therapy for 3 months prior to screening (metformin monotherapy or metformin plus dipeptidyl peptidase-4 [DPPIV], sulphonylurea [50% of the licensed dose], or a sodium-glucose co-transporter 2 [SGLT2]; and DPPIV inhibitor, sulphonylurea, or SGLT2 inhibitor is washed out prior to randomization).
排除标准
- •Females of childbearing potential and lactating females will be excluded.
研究者
相似试验
已完成
不适用
A Phase IIB, Randomized, Double-blind,Placebo-controlled study to evaluate the neutralization of the interferon gene signature and the clinical efficacy of IFNα-Kinoid in adult subjects with systemic Lupus Erythematosus-M329 Systemic lupus erythematosus, unspecifiedSystemic lupus erythematosus, unspecifiedM329PER-052-15EOVACS S.A.,,21
进行中（未招募）
1 期
Efficacy and Safety of ANB019 in Subjects with IchthyosisMedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858IchthyosisEUCTR2020-003476-41-PLAnaptysBio Inc.24
进行中（未招募）
不适用
A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial ofMultiple Dosing Regimens of ABT-719 for thePrevention of Acute Kidney Injury in SubjectsUndergoing High Risk Major SurgeryAcute Kidney InjuryEUCTR2012-005710-19-DKAbbVie Deutschland GmbH & Co. KG240
进行中（未招募）
1 期
A Phase 1 and 2 study of multiple increasing doses to evaluate the ability of MEDI0382 to produce the intended result and the safety of effects of MEDI0382 in overweight and obese subjects with Type 2 Diabetes.Type 2 Diabetes in Overweight and Obese PatientsMedDRA version: 19.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003716-36-DEMedImmune Limited, a wholly owned subsidiary of AstraZeneca107
进行中（未招募）
1 期
A Phase 1/2 Study of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1Myotonic DystrophyMedDRA version: 20.0Level: PTClassification code: 10068871Term: Myotonic dystrophy Class: 100000004850CTIS2023-506028-10-00Vertex Pharmaceuticals Inc.36